Amylyx Pharmaceuticals (AMLX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is AMLX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript…

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.…

Amylyx Pharmaceuticals (NASDAQ: AMLX) plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027 following positive late-s…

Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Courtney O'Leary Justin Klee - Co-CEO & Director Camille Bedrosian - Chief Medical Officer Dan Monahan - Chief…

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results.…

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.…

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences.…

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026.…

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.…

Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) and Dyadic International (NASDAQ: DYAI - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on…

Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Applica…

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.…

BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,82…

Almitas Capital LLC acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in a recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund ac…

Deutsche Bank AG bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in a recent quarter, according to its most recent filing with the SEC. The fund bought 557,937 shares of the company's stock, valued at a…

Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.…

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its comm…

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of it…

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, doub…

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric H…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

